OKUROnKure Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of OnKure Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OKUREsta | $116M#8 | — | 0.7x#1 | — | — | -13.0%#6 | — | -34.6%#2 | — | — | — | — |
| UNCY | $133M#2 | — | 2.5x#3 | 196.8x#2 | -29.0%#3 | 27.7%#2 | -4372.9%#3 | -49.8%#4 | — | — | 20.8%#2 | — |
| APMD | $1.1B#1 | — | — | — | — | — | — | — | — | — | — | — |
| HURA | $129M#3 | — | 7.0x#6 | — | — | -34.8%#7 | — | -167.6%#5 | -0.1%#1 | — | — | — |
| BMEA | $126M#4 | — | 10.4x#7 | — | — | 55.4%#1 | — | -509.2%#7 | — | — | — | — |
| MNOV | $123M#5 | — | 3.3x#4 | 300.4x#3 | — | 8.6%#4 | -3242.5%#2 | 32.2%#1 | — | — | 102.4%#1 | — |
| INO | $119M#6 | — | 27.2x#8 | 1819.7x#4 | -70.0%#4 | 20.6%#3 | -132871.3%#4 | -1944.6%#8 | -243.9%#2 | — | -49.5%#4 | — |
| EQ | $118M#7 | — | 2.1x#2 | 2.9x#1 | 13.9%#1 | -177.6%#8 | -57.5%#1 | -40.0%#3 | -368.9%#3 | — | — | — |
| GNLX | $107M#9 | — | 6.6x#5 | 13347.4x#5 | 0.0%#2 | -7.6%#5 | -415175.0%#5 | -199.5%#6 | -424.2%#4 | — | -42.6%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice